|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 15 March 2008, Vol. 111, No. 6, pp. 2950.
More ADO about IDO: GVHDUNIVERSITY OF BOLOGNA
In this issue of Blood, Jasperson and colleagues show that indoleamine 2,3-dioxygenase (IDO) is a novel component of the inhibition of T-cell activation after allogeneic stem-cell transplantation, and offer a rationale for innovative strategies in the management of GVHD targeting this pathway.
Graft-versus-host disease (GVHD) is the main cause of morbidity and mortality after allogeneic stem-cell transplantation. In recent years, our knowledge of the pathophysiology of GVHD has increased, but the immunological mechanisms by which GVHD is regulated at both local and systemic levels are still incompletely understood. Jasperson and colleagues have elegantly used an IDO–/– knock-out mouse model to investigate the role of IDO in the context of GVHD. Donor T cells were strictly required to up-regulate IDO expression in gut epithelial cells, and the absence of IDO resulted in increased colon GVHD, which, in turn, shortened survival of IDO–/– mice that had received transplants as compared with wt mice. Interestingly, in IDO–/– mice the major effect is described at the site of GVHD, mainly in the gut, with increased infiltration of proliferating CD4+ and CD8+ T cells, whereas little, if any, systemic effect was found (ie, activation of T cells in lymphoid organs and/or induction of T regulatory cells [Tregs]). This study reports novel findings that may have significant clinical implications. In particular, the critical role of IDO expression in orchestrating T-cell function during GVHD at the site of inflammation represents a major advance in our knowledge of the environmental effects influencing GVHD tissue injury. Moreover, these results offer a rationale for a novel approach to GVHD management. The modulation of IDO in GVHD target organs may represent an interesting strategy for limiting GVHD by acting at sites where host and donor cells interact, whereas other interventions, such as Treg-infusion therapy, may be used to induce systemic T-cell tolerance within lymphoid organs. However, an effective clinical approach to activate or enhance IDO expression once GVHD has been initiated remains to be elucidated. The preemptive induction of IDO in GVHD target organs before the occurrence of GVHD may have a more relevant clinical impact. However, the lack of IDO expression in other GVHD target tissues, such as liver and skin, indicates that mechanisms other than modulation of tryptophan catabolism may be operative in limiting GVHD in some locations. Future studies addressing these points are warranted.
Footnotes
Conflict-of-interest disclosure: The authors declare no competing financial interests.
REFERENCES
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
||||
| |||||||||||
| Copyright © 2008 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||||
